Want to see IN:AAREYDRUGS full AI Analyst Report?
AAREYDRUGS Stock Chart & Stats
₹68.03
-₹1.15(-1.99%)
At close: 4:00 PM EST
₹68.03
-₹1.15(-1.99%)
Day’s Range― - ―
52-Week Range₹50.31 - ₹101.11
Previous CloseN/A
Volume4.04K
Average Volume (3M)12.31K
Market Cap
₹2.83B
Enterprise Value₹1.91K
Total Cash (Recent Filing)₹33.98M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)65.1
Beta1.42
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.23%
Share Statistics
EPS (TTM)1.47
Shares Outstanding28,354,303
10 Day Avg. Volume16,596
30 Day Avg. Volume12,313
Financial Highlights & Ratios
PEG Ratio-13.05
Price to Book (P/B)0.96
Price to Sales (P/S)0.31
P/FCF Ratio-6.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained ProfitabilityRemaining profitable through uneven revenue periods provides a base for funding operations and preserving business resilience over time. The benefit would strengthen if cash conversion and margins improve.
Growing Equity CushionA growing equity base provides a balance-sheet cushion against operating volatility and supports continued participation in API and specialty-chemical markets. It also partially offsets the risks created by higher borrowings.
Latest Revenue ReboundThe latest revenue rebound indicates that demand for the company’s pharmaceutical and specialty-chemical products can recover after weaker periods. Sustained growth would improve plant utilization and operating leverage.
Bears Say
Weak Cash GenerationRepeatedly negative operating and free cash flow indicates that reported profits are not reliably converting into liquidity. Persistent working-capital pressure or elevated spending could increase reliance on external financing.
Rising Debt BurdenThe sharp increase in debt raises financing and balance-sheet risk while cash generation is weak. Higher obligations may restrict flexibility to fund capacity, absorb input-cost volatility, or withstand softer demand.
Thin And Declining Earnings PowerLower earnings despite a latest-period revenue rebound suggest limited pricing power or unfavorable product and input-cost mix. Thin, volatile margins reduce resilience and make sustainable profit growth more difficult.
Aarey Drugs & Pharmaceuticals Ltd. News
AAREYDRUGS FAQ
What was Aarey Drugs & Pharmaceuticals Ltd.’s price range in the past 12 months?
Aarey Drugs & Pharmaceuticals Ltd. lowest stock price was ₹50.31 and its highest was ₹101.11 in the past 12 months.
What is Aarey Drugs & Pharmaceuticals Ltd.’s market cap?
Aarey Drugs & Pharmaceuticals Ltd.’s market cap is ₹2.83B.
When is Aarey Drugs & Pharmaceuticals Ltd.’s upcoming earnings report date?
Aarey Drugs & Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 62 days.
How were Aarey Drugs & Pharmaceuticals Ltd.’s earnings last quarter?
Aarey Drugs & Pharmaceuticals Ltd. released its earnings results on Aug 14, 2026. The company reported ₹0.36 earnings per share for the quarter.
Is Aarey Drugs & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Aarey Drugs & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Aarey Drugs & Pharmaceuticals Ltd. pay dividends?
Aarey Drugs & Pharmaceuticals Ltd. pays a Notavailable dividend of ₹0.1 which represents an annual dividend yield of 0.23%. See more information on Aarey Drugs & Pharmaceuticals Ltd. dividends here
What is Aarey Drugs & Pharmaceuticals Ltd.’s EPS estimate?
Aarey Drugs & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarey Drugs & Pharmaceuticals Ltd. have?
Aarey Drugs & Pharmaceuticals Ltd. has 28,354,303 shares outstanding.
What happened to Aarey Drugs & Pharmaceuticals Ltd.’s price movement after its last earnings report?
Aarey Drugs & Pharmaceuticals Ltd. reported an EPS of ₹0.36 in its last earnings report. Following the earnings report the stock price went down -0.302%.
Which hedge fund is a major shareholder of Aarey Drugs & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:AAREYDRUGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarey Drugs & Pharmaceuticals Ltd.
Aarey Drugs & Pharmaceuticals Limited, founded in 1990 and headquartered in Mumbai, India, specializes in the production and distribution of a wide array of chemical substances. The company manufactures active pharmaceutical ingredients (APIs), bulk drugs, chemical intermediates, and specialty chemicals, supplying various industrial sectors throughout India. Its pharmaceutical offerings include key APIs such as metformin HCL, mefenamic acid, and doxophylline, alongside uracile. Additionally, Aarey produces intermediates like mono and dimethyl urea, ortho para nitro anisole, and 2 bromomethyl 1,3 dioxalane. Beyond its core manufacturing, the firm provides a broad spectrum of chemicals and industrial solvents, encompassing aromatics, chemical acids, chlor-alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, chlorinated solvents, industrial alcohols, ketones, amines, oleochemicals, olefines, phosphates, fertilizers, and monomers. The company's pharmaceutical products are utilized by both pharmaceutical formulation manufacturers and merchant exporters. Furthermore, Aarey Drugs & Pharmaceuticals Limited actively participates in the trading of industrial solvents and other chemicals.
Technical Analysis
Alpa Laboratories Limited
―
Brooks Laboratories Limited
―
Medicamen Biotech Limited
―
Medico Remedies Ltd.
―
Nectar Lifesciences Ltd.
―